CHENGDU, China, July 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab...
Hence then, the article about nmpa accepts new indication application for sacituzumab tirumotecan sac tmt as first line treatment for advanced tnbc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC )
Also on site :
- Marc Blumberg Arrested for Lewd Acts on a Child While Working at Moorpark Equestrian Facility; Additional Survivors Expected
- '70s Rock Legend, 76, Releases 'Beautiful' New Single Fans Are Calling a 'Magnificent Piece of Music'
- Ben Affleck & Jeopardy! Star Jamie Ding Take Home $1 Million on 'Millionaire' After a Surprise Assist on the Final Answer